El.En. SpAELEAF 69 EPS without NRI is $0.48 as of Mar. 2026. GuruFocus rates ELEAF with a GF Score™ of 69/100 and a GF Value™ of $12.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 666 Medical Devices & Instruments companies, El.En. SpA ranks worse than 67.57% on this metric.
El.En. SpA's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $0.29.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.48.
During the past 12 months, El.En. SpA's average earnings per share (NRI) Growth Rate was -9.70% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -4.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 16.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 16.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for El.En. SpA's EPS without NRI or its related term are showing as below:
ELEAF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.1 Med: 9.5 Max: 189
Current: -4
During the past 13 years, El.En. SpA's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 189.00% per year. The lowest was -60.10% per year. And the median was 9.50% per year.
ELEAF's 3-Year EPS without NRI Growth Rate is ranked worse than 67.57% of 666
companies
in the Medical Devices & Instruments industry
Industry Median: 8.15
vs ELEAF: -4.00
El.En. SpA's EPS (Diluted) for the
three
months ended in Mar. 2026 was $0.29.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.48.
El.En. SpA's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.29.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.48.
El.En. SpA (OTCPK:ELEAF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
El.En. SpA EPS without NRI Related Terms
El.En. SpA EPS without NRI Historical Data
* Premium members only.
The historical data trend for El.En. SpA's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELEAF vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, El.En. SpA's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El.En. SpA PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, El.En. SpA's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where El.En. SpA's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El.En. SpA (ELEAF) has a EPS without NRI of $0.48 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on El.En. SpA and its competitors. According to the industry distribution chart, El.En. SpA ranks #450 out of 666 companies in the Medical Devices & Instruments industry, placing it in the top 67.6%.
Is El.En. SpA's EPS without NRI too high?
El.En. SpA's current EPS without NRI is $0.48. The Medical Devices & Instruments industry median EPS without NRI is 8.15. El.En. SpA's value of $0.48 is 94.1% below this industry median. Based on the distribution chart, El.En. SpA ranks #450 out of 666 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, El.En. SpA has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does El.En. SpA's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, El.En. SpA ranks #450 out of 666 companies for EPS without NRI. This places El.En. SpA in the lower half of its industry. The industry median EPS without NRI is 8.15. El.En. SpA's value of $0.48 is 94.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El.En. SpA's current EPS without NRI of $0.48 is 94.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on El.En. SpA and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El.En. SpA's current EPS without NRI is $0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El.En. SpA stock overvalued right now?
Based on GuruFocus' analysis, El.En. SpA (ELEAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $12.41, compared to a current price of $18.50 — trading 49.1% above its estimated fair value. The current EPS without NRI is $0.48 and 94.1% below the Medical Devices & Instruments industry median of 8.15. El.En. SpA's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For El.En. SpA (ELEAF), the current EPS without NRI is $0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is El.En. SpA (ELEAF) Overvalued in 2026?
Based on GuruFocus' analysis, El.En. SpA stock appears to be overvalued.
The current stock price of $18.50 is trading 49.1% above its estimated GF Value™ of $12.41.
GuruFocus considers El.En. SpA to be Significantly Overvalued.
Key valuation signals for ELEAF:
EPS without NRI: $0.48
GF Value™: $12.41 vs. price of $18.50 (49.1% above fair value)
Industry Position: 94.1% below the Medical Devices & Instruments median (#450 of 666)
No single metric tells the full story. See the ELEAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
El.En. SpA is engaged in the research and development, manufacturing, distribution, and sales of laser systems. The company operates in two divisions: medical and industrial. In the medical division, the application of laser is used as a healing treatment for aesthetic, surgical, physiotherapy and dental. Industrial division develops solutions for laser material processing applications through cutting, marking, laser sources and restoration. The company generates the majority of its revenue from the medical division. Geographically, it derives maximum revenue from the Rest of the World.
69GF Score
Get the complete analysis for ELEAF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELEAF has been successfully added to your 
